AstraZeneca PLC (FRA:ZEG)
126.95
+0.60 (0.47%)
Last updated: Sep 29, 2025, 5:42 PM CET
AstraZeneca Employees
AstraZeneca had 94,300 employees as of December 31, 2024. The number of employees increased by 4,400 or 4.89% compared to the previous year.
Employees
94,300
Change (1Y)
4,400
Growth (1Y)
4.89%
Revenue / Employee
€510,187
Profits / Employee
€74,901
Market Cap
197.31B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 94,300 | 4,400 | 4.89% |
Dec 31, 2023 | 89,900 | 6,400 | 7.66% |
Dec 31, 2022 | 83,500 | 400 | 0.48% |
Dec 31, 2021 | 83,100 | 7,000 | 9.20% |
Dec 31, 2020 | 76,100 | 5,500 | 7.79% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
Company Name | Employees |
---|---|
SAP SE | 109,121 |
Siemens Aktiengesellschaft | 327,000 |
Deutsche Telekom AG | 198,194 |
Allianz SE | 156,626 |
Rheinmetall AG | 28,539 |
Siemens Energy AG | 98,000 |
Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft in München | 44,224 |
Deutsche Bank Aktiengesellschaft | 89,753 |
AstraZeneca News
- 4 days ago - A New Prescription For Pain: Understanding Trump's 100% Pharma Tariff - Seeking Alpha
- 4 days ago - AstraZeneca to Offer Discounted Drugs As Trump Pressures Pharma Industry to Cut Prices - WSJ
- 4 days ago - AstraZeneca launches direct-to-consumer platform to expand access to medications for US patients, including those living with chronic conditions - Business Wire
- 4 days ago - AstraZeneca to cut some direct-to-patient US drug prices after Trump demand - Reuters
- 5 days ago - AstraZeneca: Oncology Breakthroughs And Farxiga Surge Excite Investors - Seeking Alpha
- 6 days ago - Moderna boss defends UK in drug-pricing row as he opens £150m Oxfordshire facility - The Guardian
- 6 days ago - AstraZeneca (AZN) Receives FDA Priority Review for Enhertu - GuruFocus
- 6 days ago - AstraZeneca, Daiichi Sankyo under priority review of FDA for breast cancer - Seeking Alpha